Research ArticleArticle
Effect of a Single Apolipoprotein L1 Gene Nephropathy Variant on the Risk of Advanced Lupus Nephritis in Brazilians
Gisele Vajgel, Suelen Cristina Lima, Diego Jeronimo S. Santana, Camila B.L. Oliveira, Denise Maria N. Costa, Pamela J. Hicks, Maria Alina G.M. Cavalcante, Carl D. Langefeld, Lucila Maria Valente, Sergio Crovella, Gianna Mastroianni Kirsztajn, Barry I. Freedman and Paula Sandrin-Garcia
The Journal of Rheumatology November 2019, jrheum.190684; DOI: https://doi.org/10.3899/jrheum.190684
Gisele Vajgel
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Suelen Cristina Lima
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Diego Jeronimo S. Santana
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Camila B.L. Oliveira
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Denise Maria N. Costa
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Pamela J. Hicks
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Maria Alina G.M. Cavalcante
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Carl D. Langefeld
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Lucila Maria Valente
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Sergio Crovella
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Gianna Mastroianni Kirsztajn
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Barry I. Freedman
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Paula Sandrin-Garcia
From the Division of Nephrology, Hospital das Clinicas, Federal University of Pernambuco (UFPE); Molecular Biology Laboratory, Keizo Asami Immunopathology Laboratory (LIKA), UFPE; Division of Nephrology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil; Division of Public Health Sciences, Department of Biostatistical Sciences, and Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA; Division of Nephrology, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, Brazil. Supported by US National Institutes of Health grants R01 DK084149 and R01 DK070941 (both to Dr. Freedman). Wake Forest University Health Sciences and Dr. Freedman have rights to an issued US patent related to APOL1 genetic testing (www.apol1genetest.com). Dr. Freedman is a consultant for AstraZeneca Pharmaceuticals and Renalytix AI. G. Vajgel, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Molecular Biology Laboratory, LIKA, UFPE; S.C. Lima, PhD, Molecular Biology Laboratory, LIKA, UFPE; D.J. Santana, UG, Molecular Biology Laboratory, LIKA, UFPE; C.B. Oliveira, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; D.M. Costa, MD, Division of Nephrology, Hospital das Clinicas, UFPE, and Division of Nephrology, IMIP; P.J. Hicks, BS, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; M.A. Cavalcante, MD, Division of Nephrology, Hospital das Clinicas, UFPE; C.D. Langefeld, PhD, Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine; L.M. Valente, MD, PhD, Division of Nephrology, Hospital das Clinicas, UFPE; S. Crovella, PhD, Molecular Biology Laboratory, LIKA, UFPE; G.M. Kirsztajn, MD, PhD, Division of Nephrology, Department of Medicine, UNIFESP; B.I. Freedman, MD, Center for Diabetes Research, and Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine; P. Sandrin- Garcia, PhD, Molecular Biology Laboratory, LIKA, UFPE. Address correspondence to Dr. G. Vajgel, Federal University of Pernambuco (UFPE), Nephrology, Av. Prof Moraes Rego, 1235 Recife, Pernambuco, Brazil. E-mail: giselevajgel@hotmail.com. Accepted for publication November 4, 2019.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Effect of a Single Apolipoprotein L1 Gene Nephropathy Variant on the Risk of Advanced Lupus Nephritis in Brazilians
Gisele Vajgel, Suelen Cristina Lima, Diego Jeronimo S. Santana, Camila B.L. Oliveira, Denise Maria N. Costa, Pamela J. Hicks, Maria Alina G.M. Cavalcante, Carl D. Langefeld, Lucila Maria Valente, Sergio Crovella, Gianna Mastroianni Kirsztajn, Barry I. Freedman, Paula Sandrin-Garcia
The Journal of Rheumatology Nov 2019, jrheum.190684; DOI: 10.3899/jrheum.190684
Effect of a Single Apolipoprotein L1 Gene Nephropathy Variant on the Risk of Advanced Lupus Nephritis in Brazilians
Gisele Vajgel, Suelen Cristina Lima, Diego Jeronimo S. Santana, Camila B.L. Oliveira, Denise Maria N. Costa, Pamela J. Hicks, Maria Alina G.M. Cavalcante, Carl D. Langefeld, Lucila Maria Valente, Sergio Crovella, Gianna Mastroianni Kirsztajn, Barry I. Freedman, Paula Sandrin-Garcia
The Journal of Rheumatology Nov 2019, jrheum.190684; DOI: 10.3899/jrheum.190684